Europe Branded Generics Market Size & Outlook, 2021-2030
Europe branded generics market, 2018-2030 (US$M)
Related Markets
Europe branded generics market highlights
- The Europe branded generics market generated a revenue of USD 35.9 billion in 2021.
- The market is expected to grow at a CAGR of 4.9% from 2022 to 2030.
- In terms of segment, anti-hypertensive was the largest revenue generating drug class in 2021.
- Hormones is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, Italy is expected to register the highest CAGR from 2022 to 2030.
Europe data book summary
| Market revenue in 2021 | USD 35.9 billion |
| Market revenue in 2030 | USD 55.4 billion |
| Growth rate | 4.9% (CAGR from 2021 to 2030) |
| Largest segment | Anti-hypertensive |
| Fastest growing segment | Hormones |
| Historical data covered | 2018 - 2020 |
| Base year for estimation | 2021 |
| Forecast period covered | 2022 - 2030 |
| Quantitative units | Revenue in USD billion |
| Market segmentation | Alkylating Agents, Antimetabolites, Hormones, Anti-hypertensive, Lipid Lowering drugs, Anti-depressants, Anti-psychotics, Anti-epileptics |
| Key market players worldwide | Teva Pharmaceutical Industries Ltd, Lupin, Sanofi SA, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, GlaxoSmithKline, Pfizer Inc, Apotex Inc., Viatris Inc |
Other key industry trends
- In terms of revenue, Europe region accounted for 15.7% of the global branded generics market in 2021.
- Globally, Asia Pacific is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 188.0 billion by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Branded Generics Market Scope
Branded Generics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe branded generics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to branded generics market will help companies and investors design strategic landscapes.
Anti-hypertensive was the largest segment with a revenue share of 15.6% in 2021. Horizon Databook has segmented the Europe branded generics market based on alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptics covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing government initiatives, rising disease burden of chronic illnesses, and presence of major manufacturers in this region drive market growth in the European region. In addition, countries are focusing on development of their manufacturing hubs and reducing dependency on Asian countries, such as India and China, for generic products & APIs.
Moreover, key players engaged in the development and commercialization of generic drugs are expected to contribute to market growth. However, stringent government regulation and uneven reimbursement policies in some EU countries may restrain market growth in Europe.
To overcome these challenges, governments are investing on healthcare sector and changing the pricing policies for generic products. In 2018, the healthcare expenditure on pharmaceuticals was reported to be USD 177 billion in EU-5 (UK, Germany, France, Spain, and Italy).
Reasons to subscribe to Europe branded generics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe branded generics market databook
-
Our clientele includes a mix of branded generics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe branded generics market , including forecasts for subscribers. This continent databook contains high-level insights into Europe branded generics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe branded generics market size, by country, 2018-2030 (US$M)
Europe Branded Generics Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
